Continuous High-Dose Intravenous Vitamin C:
An Early Safety Study in Patients with Advanced Cancer
High-dose intravenous vitamin C, or intravenous ascorbate, differs from routine oral vitamin supplementation because intravenous administration can produce substantially higher blood concentrations of ascorbate.
One important question in early clinical research was what would happen when higher-dose ascorbate was given continuously to patients with advanced cancer, particularly in terms of safety, tolerability, and plasma concentration.
What Did the Study Do?
The primary aim was not to establish antitumor efficacy, but to examine the safety, tolerability, and feasibility of continuous high-dose intravenous ascorbate in patients with very advanced disease.
24
150–710
~10–50 g
≤8 weeks
Key Parameters Monitored During the Study
What Happened to Plasma Ascorbate Levels?
Many participants entered the study with relatively low vitamin C levels. After continuous intravenous infusion, plasma ascorbate concentrations increased substantially.
~1.1 mM
During treatment, the average plasma ascorbate concentration increased to approximately 1.1 mM.
The significance of this observation is that intravenous administration can achieve millimolar plasma concentrations that are difficult to reach with routine oral supplementation.
What Adverse Events Were Reported?
Most reported adverse effects were mild, but the study also documented two Grade 3 adverse events considered possibly related to the study intervention.
Nausea
Edema
Dry Mouth or Dry Skin
Kidney Stone
One patient with a prior history of kidney stones developed nephrolithiasis after approximately 13 days of infusion. This finding highlights the importance of considering previous renal and urinary tract risk factors.
Hypokalemia
Another patient developed low serum potassium after approximately six weeks of continuous infusion. This underscores the importance of monitoring electrolytes during prolonged high-dose intravenous administration.
“Generally Tolerable” Does Not Mean Risk-Free
Some renal function markers did not show clear overall deterioration during the study, but clinically meaningful adverse events still occurred in individual patients. Medical history review and ongoing clinical monitoring therefore remain important.
Did the Study Demonstrate Tumor Control?
No. The study was not designed primarily to establish antitumor efficacy, and most participants did not demonstrate objective tumor control.
The report described only one patient with stable disease, who continued the related treatment approach for a longer period after the study.
A Single Case of Stable Disease Does Not Establish Overall Efficacy
With no control group, only 24 participants, and a population with very advanced disease, one case of disease stability cannot establish that high-dose intravenous vitamin C has a definite tumor-control effect.
How Should This Study Be Interpreted?
The main value of this study lies in its early safety and tolerability data, not in demonstrating that high-dose intravenous vitamin C can control cancer.
Only 24 Patients
The small sample makes it difficult to reliably identify uncommon adverse events or generalize the findings to the broader cancer populatio
No Control Group
There was no placebo group or concurrent standard-care comparison group, so changes in disease status cannot be reliably attributed to the study intervention.
Efficacy Was Not the Primary Question
Participants were medically fragile, the study duration was relatively short, and most had previously received other cancer treatments. Efficacy was therefore not the principal question the study was designed to answer.
The Study Provides a Safety Signal, Not Proof of Anticancer Efficacy
A reasonable interpretation is that this small pilot study provided early information on the tolerability and feasibility of continuous high-dose intravenous ascorbate in some patients with advanced cancer, but it did not establish a definite anticancer effect.
Why Was This Study Important for Later Research?
The study showed that intravenous administration could raise plasma ascorbate concentrations into the millimolar range, which is substantially different from concentrations typically achieved with oral vitamin C.
Later clinical research therefore increasingly focused on the safety, dosing, pharmacokinetics, and feasibility of “pharmacologic ascorbate,” including its use alongside different standard cancer treatment approaches.
However, results from human studies remain inconsistent. Some studies have reported signals involving quality of life or treatment-related adverse effects, but whether intravenous vitamin C provides definite tumor-control or survival benefits still requires higher-quality clinical evidence.
How Does BMS Clinic View This Evidence?
High-dose intravenous vitamin C is not the same as routine nutritional supplementation. Its use requires consideration of infusion dose, kidney function, history of kidney stones, G6PD status, electrolyte balance, and the patient’s current cancer treatment plan.
This study also reminds us that even when overall tolerability appears acceptable in a small trial, individual patients may still experience clinically significant adverse events. Appropriate medical assessment and monitoring are therefore important.
BMS Clinic emphasizes evaluation based on current medical evidence and each patient’s individual health status. If high-dose intravenous vitamin C is considered as part of supportive medical care, it should be integrated with the patient’s existing cancer management and should not be understood as a replacement for standard cancer care.
This page is provided for medical education and literature reference only. It is intended to help readers understand early safety research on continuous high-dose intravenous vitamin C in patients with advanced cancer and does not replace professional medical assessment or advice.
The study discussed was a small, single-arm pilot study primarily designed to evaluate safety and feasibility. It did not establish that high-dose vitamin C can control cancer, reduce tumour size, or prolong survival.
Patients with cancer considering high-dose intravenous vitamin C should undergo assessment and monitoring by qualified healthcare professionals, taking into account their medical condition, kidney function, history of kidney stones, G6PD status, and current cancer care.
Learn More About High-Dose Intravenous Vitamin C Support
This early study primarily provides information on the safety and tolerability of continuous high-dose intravenous vitamin C, and does not establish a confirmed benefit in tumour control or survival. Anyone considering this type of medical support should first undergo appropriate assessment of kidney function, G6PD status, kidney stone risk, electrolyte levels, and current cancer care.
References
Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients. P R Health Sci J. 2005;24(4):269–276.
National Cancer Institute. Intravenous Vitamin C (PDQ®) – Health Professional Version. National Cancer Institute.